Congratulations to Allos AI on their recent funding success! The NHS Market Access Accelerator (MAA) alumnus company has secured $5million in seed financing, led by Oxford Science Enterprises (OSE). This round also included investment from the University of California accelerator Berkeley SKYDECK, and Habico Invest, the family office of Danish pharmaceutical group, Orifarm. The funding will support expansion across formulation development and data science.
Allos is a causal AI which simulates how interventions affect outcomes, defining a robust operating window before experiments run. The closed-loop system learns from every run and deviation, serving as a single source of truth with traceable drivers, documented assumptions, and controlled version history.
It also reformulates complex drugs by modelling how formulation, dosing, delivery and patient biology interact to impact clinical outcomes. Their technology allows a bending of the cost-risk curve of drug development and formulation for complex generics, making specialty medicine easier to take, optimised for long-term use and economically viable.
For more information on Allos and their causal AI, visit their website.